Company Description
NanoVibronix, Inc., through its subsidiary, NanoVibronix Ltd., focuses on the non-invasive biological response-activating devices that target biofilm prevention, wound healing, and pain therapy in the United States, Israel, Europe, Australia, India, and internationally.
The company’s product portfolio includes UroShield, an ultrasound-based product to prevent bacterial colonization and biofilm in urinary catheters, enhance antibiotic efficacy, and decrease pain and discomfort associated with urinary catheter use.
It also offers PainShield, a patch-based therapeutic ultrasound technology to treat pain, muscle spasm, and joint contractures; and WoundShield, a patch-based therapeutic ultrasound device intended to facilitate tissue regeneration and wound healing by using ultrasound to increase local capillary perfusion and tissue oxygenation.
It sells its products directly to patients, as well as through distributor agreements. The company was incorporated in 2003 and is headquartered in Tyler, Texas.
| Country | United States |
| Founded | 2003 |
| Industry | Medical Devices |
| Sector | Healthcare |
| Employees | 16 |
| CEO | Brian Murphy |
Contact Details
Address: 969 Pruitt Avenue Tyler, Texas 77569 United States | |
| Phone | (914) 233-3004 |
| Website | nanovibronix.com |
Stock Details
| Ticker Symbol | NAOV |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001326706 |
| CUSIP Number | 63008J108 |
| ISIN Number | US63008J6038 |
| SIC Code | 3842 |
Key Executives
| Name | Position |
|---|---|
| Brian M. Murphy | Chief Executive Officer and Director |
| Stephen R. Brown CPA | Chief Financial Officer |
| Dr. Harold Jacob M.D. | Chief Medical Officer and Director |
| Amir Rippel | Vice President of Marketing |
| Lindsey Harrison | Vice President of Sales |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Nov 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Nov 14, 2024 | 10-Q | Quarterly Report |
| Oct 29, 2024 | ARS | Filing |
| Oct 29, 2024 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Oct 29, 2024 | DEF 14A | Other definitive proxy statements |
| Oct 11, 2024 | 8-K | Current Report |
| Oct 7, 2024 | 8-K | Current Report |
| Sep 25, 2024 | 8-K | Current Report |
| Aug 14, 2024 | 10-Q | Quarterly Report |
| May 16, 2024 | 8-K | Current Report |